James Winbush, MD
Internal Medicine · Anderson, SCNPI 1912008806
Payments from drug & device makers
Across 348 payments — averaging $12.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$542
- Pfizer$521
- Novo Nordisk$485
- Bayer$399
- Johnson & Johnson$367
- Lilly USA, LLC$328
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,186100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $542 |
| Pfizer | 37 | $521 |
| Novo Nordisk | 62 | $485 |
| Bayer | 50 | $399 |
| Johnson & Johnson | 19 | $367 |
| Lilly USA, LLC | 15 | $328 |
| AstraZeneca | 15 | $217 |
| GSK | 12 | $182 |
| Amgen | 8 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $131 |
| Amarin Pharma, Inc. | 6 | $125 |
| Antares Pharma, Inc. | 5 | $83 |
| Nabriva Therapeutics, PLC | 5 | $81 |
| Paratek Pharmaceuticals, Inc. | 3 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Indivior Inc. | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Novartis | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Avion Pharmaceuticals | 1 | $23 |
| Orexo US, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Incyte Corporation | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Merck | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$4,207 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $100,142 |
| JardianceEmpagliflozin | 71 | $72,507 |
| OzempicSemaglutide | 43 | $48,230 |
| EliquisApixaban | 39 | $44,677 |
| EntrestoSacubitril/Valsartan | 26 | $37,898 |
| VraylarCariprazine Hcl | 18 | $28,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $25,458 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $24,704 |
| FarxigaDapagliflozin Propanediol | 20 | $21,570 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $17,571 |
| RybelsusSemaglutide | 11 | $17,440 |
| LinzessLinaclotide | 19 | $16,680 |
| Dexlansoprazole DrDexlansoprazole | 36 | $12,908 |
| CreonLipase/Protease/Amylase | 11 | $11,791 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $10,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $328 | $100,14282 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $12 | $97,21291 claims |
| AbbVieVraylar, Namzaric, Linzess, Creon | $542 | $74,85562 claims |
| Novo NordiskOzempic, Rybelsus | $485 | $65,67054 claims |
| PfizerEliquis | $521 | $44,67739 claims |
| NovartisEntresto | $35 | $37,89826 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $217 | $32,56831 claims |
| GSKTrelegy Ellipta | $182 | $25,45831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Anderson
- Carl SofleyAnderson$673K
- Anita VagnoniAnderson$21K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.